Foreword | George Freeman
The NHS as a global resource of healthcare expertise
The British NHS is already respected around the world as a world-class leader in healthcare. With expert capabilities gained through 66 years of experience the NHS is a fantastic resource of healthcare knowledge and technological advancements.
This expertise means the NHS can take a leading role in a broader global push to create more efficient and successful healthcare models. My central mission is to define a world in which
governments can view healthcare as not just a cost to the Exchequer but also as a major economic asset. With ever rising healthcare demands, we need to spend every healthcare pound in a way that delivers more care and creates new markets for innovation that attracts international investment to the UK. We need to move away from thinking of healthcare as something ‘done to us’ by government, but something 21st century “healthcare citizens” have more power over ourselves. Prevention, patient empowerment and precision medicines are the watchwords of 21st century healthcare. Over the last year UK health organisations have
won contracts worth £550m, £200m ahead of target, highlighting the huge global potential of the NHS. With £10.8bn worth of overseas opportunities identified there is confidence that the UK can continue to improve the quality of healthcare delivery to our valued international partners. Life sciences are about manufacturing as well
as research. The production of modern medicines is one of the UK’s leading manufacturing sectors, with exports worth over £22 billion ($35.86 billion). The Medicines Manufacturing Industry Partnership is helping ensure we remain at the forefront of this highly competitive sector, building on the impressive work they have already led in areas like detailed innovation mapping and modern skills investment. Last year I launched a wide-ranging review of the
way new drugs and medical devices are developed and adopted in the UK. The aim is to accelerate patient access to innovation while lowering costs for industry and the NHS. I believe new measures outlined in The Innovative Medicines and Medical Technologies Review could shave years off the time
global-opportunity.co.uk
it takes to bring a drug to market and make the NHS more of a partner in innovation. Key to the strategy will be in aligning the interests
of the pharma, biotech and medical technologies sectors with the publicly-funded National Health Service to improve treatment for patients and boost the economy at the same time. NHS leadership in health research is attracting
new investment into our life sciences research sector, generating the health and wealth we need to be a modern economy. A Minister for Life Sciences is every bit as much about data, diagnostics and devices; and with the advances in genomics, finding cures for diseases will increasingly come from clinicians working much closer with patient data. We will see more personalised drugs, more devices using diagnostics and informatics, transforming the way 21st century healthcare is delivered. I want to ensure that patients up and down Britain
can get access to important medical innovations as soon as possible. By revolutionising the way in which we look at getting medicines and devices into the NHS we will make sure that the UK is the best place in the world for 21st century medical innovation, research, testing and adoption.
George Freeman MP Minister for Life Sciences
The production of modern medicines is one of the UK’s leading manufacturing
sectors, with exports worth over £22 billion ($35.86 billion).’
Issue 01 | Global Opportunity Healthcare 2015 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204